<DOC>
	<DOCNO>NCT02586623</DOCNO>
	<brief_summary>To evaluate time treatment intervention patient Parkinson 's Disease ( PD ) , Multiple System Atrophy ( MSA ) , Pure Autonomic Failure ( PAF ) , Non-Diabetic Autonomic Neuropathy ( NDAN ) Dopamine Beta Hydroxylase ( DBH ) Deficiency previously stabilize droxidopa therapy symptom neurogenic orthostatic hypotension ( NOH ) ( dizziness , light-headedness , feeling black )</brief_summary>
	<brief_title>Sustained Effect Droxidopa Symptomatic Neurogenic Orthostatic Hypotension</brief_title>
	<detailed_description>This multi-site , placebo-controlled , double-blind , randomized withdrawal , time intervention study duration 36 week , consist 5 period : Screening Period : 4 week duration ; Open-Label Titration Period ( Titration Period ) : 4 week duration ; Open-Label Treatment Period ( Open-Label Period ) : 12 week duration ; Double-Blind Treatment Period ( Double-Blind Period ) : 12 week duration ; Safety Follow-Up Period : 4 week duration</detailed_description>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<mesh_term>Droxidopa</mesh_term>
	<criteria>18 year older able stand ( without limit assistance ) Clinical diagnosis symptomatic orthostatic hypotension associate Primary Autonomic Failure ( PD , MSA PAF ) NDAN DBH Deficiency Score least 4 great Orthostatic Hypotension Symptom Assessment ( OHSA ) Item # 1 ( measure Screening [ Visit 1 ] first Titration Visit [ Visit 2a ] prior dose ) A document drop least 20 millimeter mercury ( mmHg ) SBP , within 3 minute stand . This either document patient history assess Screening prior first Titration Visit ( Visit 2a ) Additional inclusion criterion patient take prescribed droxidopa prior study entry : Patients take prescribed droxidopa therapy eligible participate study meet inclusion criterion also stable dose prescribe droxidopa least 2 week prior Screening Visit ( Visit 1 ) . In addition , must meet either follow Screening Visit ( Visit 1 ) : The patient 's Visit 1 OHSA Item # 1 score ≥ 7 AND prescribe dose ≤ 300 mg three time daily ( TID ) ; OR The patient 's Visit 1 OHSA Item # 1 score ≤6 AND worsen ≥ 2 unit retested wash droxidopa least 3 day In investigator 's opinion , patient able understand cooperate study procedure Known suspect alcohol substance use disorder within past 12 month ( DSM5 criterion ) Women pregnant breastfeed Women childbearing potential ( WOCP ) use least one method contraception partner Sustained supine hypertension great equal 180 mmHg systolic 110 mmHg diastolic . Sustained defined average 3 observation least 10 minute apart patient supine rest least 5 minute prior measurement . Untreated close angle glaucoma Diagnosis hypertension require treatment antihypertensive medication ( shortacting antihypertensive treat nocturnal supine hypertension allow study ) Any significant uncontrolled cardiac arrhythmia History myocardial infarction , within past 2 year Current unstable angina Congestive heart failure ( NYHA Class 3 4 ) Diabetic autonomic neuropathy Additional protocol define inclusion exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>